Our Service

Selected literature about the preclinical and clinical development of Urodilatin:

Reviews
Forssmann WG, Meyer M, Forssmann K: The renal urodilatin system: clinical implications. Cardiovascular Research 51 (2001) 450-462

Markus Meyer: Urodilatin - Von Entdeckung zu klinischer Anwendung. I. Holzapfel Verlag München. (1997)

Forssmann WG, Richter R, Meyer M: The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol (1998); 110: 335-57

Preclinic
Schulz-Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R., Forssmann W.G.: Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin. Wochenschr. (1988) 66, 752-759

Gagelmann M, Hock D, Forssmann WG: Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptide from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (a-hANP/CDD-99-120). FEBS Lett (1988); 233: 249-54

Gagelmann M, Feller S, Hock D, Schulz-Knappe P, Forssmann WG: Biochemistry of the differential release, processing and degradation of cardiac and related peptide hormones. In: Kaufmann W, Wambach G, eds. Endocrinlogy of the heart. Berlin, Heidelberg: Springer-Verlag, (1989): 27-40

Duft S, Marxen P, Deeb M, Kuhn M, Piepenbrock S, Forssmann WG, Frölich JC: Urodilatin and atrial natriuretic factor relax preconstricted isolated perfused guinea pig trachea and increase cyclic GMP. Naunyn-Schmiedeberg's Arch Pharmacol (1992); 345 (Suppl 2): R49 (abstract)

Riegger G.A.J., Elsner D., Schulz-Knappe P., Forssmann W.G., Kromer E.P.: The new peptide ANP-95-126 in dogs with and without heart failure. Cardiovasc. Drugs Ther. (1989) 3, 623

Riegger G.A.J., Elsner D., Forssmann W.G. et al.: Effects of ANP-(95-126) in dogs before and after induction of heart failure. Am. J. Physiol. (1990) 259, H1643-H1648

Flüge T, Hoymann HG, Hohlfeldt J, Heinrich U, Fable H, Wagner TOF, Forssmann WG: Type A natriuretic peptides exhibit different bronchoprotective effects in rats. Eur J Pharmacol (1994); 271: 395-402

Phase I
Saxenhofer H., Raselli A., Weidmann P., Forssmann W.G., Bub A., Ferrari P., Shaw S.G.: Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am. J. Physiol. (1990) 259, F832-F838

Kentsch M., Ludwig D., Drummer C., Gerzer R., Mueller-Esch G.: Haemodynamic and renal effects of urodilatin in healthy volunteers. Eur. J. Clin. Invest. (1992) 22, 319-325

Meyer M., Richter R., Brunkhorst R, Wrenger E., Schulz-Knappe P., Kist A., Mentz P., Brabant E.G., Koch K.M., Rechkemmer G., Forssmann W.G.: Urodilatin is involved in sodium homeostasis and exerts sodium-state dependent natriuretic and diuretic effects. Am J Physiol (1996); 271: 489-497.

Carstens J., Jensen K.T., Pedersen E.B.: Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Clin Sci. (1997); 92:397-407.

Carstens J., Jensen K.T., Pedersen E.B.: Metabolism and action of urodilatin infusion in healthy volunteers. Clin Pharmacol Ther (1998); 64:73-86

Bestle M.H., Olsen N.V., Christensen P., Jensen B.V., Bie P.: Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. Am J Physiol. (1999); 276:R684-95

Phase II

Heart Failure
Ludwig D., Kentsch M., Wiemer A., Ludwig H.J., Drummer C., Gerzer R., Mueller-Esch G.: Urodilatin und ANF (99-126): Vergleich der Effekte bei Herzinsuffizienz (Urodilatin and ANF (99-126): Comparison of the effects in heart failure). Z. Kardiol. (1991) 80, 105-106

Kentsch M., Ludwig D., Drummer C., Gerzer R., Mueller-Esch G.: Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur. J. Clin. Invest. (1992) 22 (10), 662-669

Elsner D., Muders F., Müntze A., Kromer E.P., Forssmann W.G., Riegger, G.A.J.: Efficacy of prolonged infusion of urodilatin (ANP-(95-126)) in patients with congestive heart failure. Am Heart J. (1995) 129, 766-773

Renal Failure
Hummel M, Kuhn M, Bub A, Bittner H, Kleefeld D, Marxen P, Schneider B, Hetzer R, Forssmann WG: Urodilatin. A new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients. Clin Invest (1992): 70 (No. 8): 674-682

Hummel M., Kuhn M., Bub A., Mann B., Schneider B., von Eickstedt K.-W., Forssmann W.-G., Hetzer R.: Urodilatin, a new therapy to prevent kidney failure after heart transplantation. J Heart Lung Transplant. (1993); 12:209-18

Cedidi C, Meyer M, Kuse ER, Schulz-Knappe P, Ringe B, Frei U, Pichlmayr R, Forssmann WG: Urodilatin: a new approach for the treatment of therapy-resistant acute renal failure after liver transplantation. Eur J Clin Invest (1994); 24: 632-639

Laws H.J., Kropp S., Meyer M., Forssmann W.-G., Burdach S.: Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18-month-old boy. Bone Marrow Transplant. (1995); 16: 307-10

Brenner P, Meyer M, Reichenspurner H, Meiser B, Müller R, Mentz P, Schulz-Knappe P, Überbacher HJ, Kreutzer E, Überführ P, Guder WG, Wenzlaff H, Teschemacher H, Reichart B, Forssmann WG Significance of prophylactic urodilatin (INN: Ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation. Eur J Med Res 1: 137-143, (1995/96)

Wiebe K., Meyer M., Wahlers T., Zenker D., Schulze F.-P., Michels P., Dalichau H., Mohr F.W., Borst H.-G., Forssmann W.-G.: Acute renal failure following cardiac surgery is reverted by administration of urodilatin (INN: Ularitide). Eur J Med Res 1: 259-65, (1995/96)

Kuse E.R., Meyer M., Constantin R., Odhafer K., Schlitt H.-J., Schulz-Knappe P., Überbacher H.J., Pichmayr R., Forssmann W.-G.: [Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation]. Anaesthesist. (1996); 45:351-8

Meyer M., Wiebe K., Wahlers T., Zenker D., Schulze F.-P., Michels P., Forssmann W.-G.: Urodilatin (INN:ularitide) as a new drug for the therapy of acute renal failure following cardiac surgery. Clin Exp Pharmacol Physiol. (1997); 24:374-6

Langrehr J.M., Kahl A., Meyer M., Neumann U., Knoop M., Jonas S., Steinmüller T., Bechstein W.O. Frei U. Forssmann W.-G., Neuhaus P.:Prophylactic use of low-dose urodilatin for prevention of renal impairment following liver transplantation: a randomized placebo-controlled study. Clin Transplant. (1997); 11: 593-8

Meyer M., Pfarr E., Schirmer G., Überbacher H.J., Schöpe K., Böhm E., Flüge T., Mentz P., Scigalla P., Forssmann W.G.: Therapeutic Use of the Natriuretic Peptide Ularitide in Acute Renal Failure. Renal Failure (1999) 21, 85-100

Bronchial Asthma
Flüge T., Fabel H., Wagner T.O.F., Schneider B., Forssmann W.G.: Urodilatin (Ularitide, INN): a potent bronchodilator in asthmatic subjects. Eur. J. Clin. Invest. (1995) 25, 728-736

Flüge T, Fabel H, Wagner TOF, Schneider B, Forssmann WG: Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics. Regulatory Peptides (1995); 59: 357-70

Flüge T, Forssmann WG, Kunkel G, Schneider B, Mentz P, Forssmann K, Barnes PJ, Meyer M: Bronchodilation using combined urodilatin - albuterol administration in asthma: a randomized, double-blind, placebo-controlled trial. Eur J Med Res (1999); 4: 411-5

Forssmann K., Zippel B., Verleger C., Mentz P., Meyer M., Kunkel G., Forssmann W.G.: Effects of Urodilatin in Patients with Severe Asthma. ( Abstract) European Respiratory Society, Annual Congress, Madrid. (1999)